DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pontocerebellar hypoplasia, type 1C — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePontocerebellar hypoplasia, type 1C maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pontocerebellar hypoplasia, type 1c is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
exosome component 8 (EXOSC8) — EXOSC8 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet anpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6D6Q · 3.45 Å · ligand PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER (ANP). Experimental structure, not a prediction.
What the evidence adds up to
Pontocerebellar hypoplasia is a group of autosomal recessive neurodevelopmental disorders defined by abnormal formation and function of the pons, cerebellum and cerebrum. A review covering literature from 1912 to 2022 identified 191 publications and found that the most frequently reported types are 1, 2 and 6, while types 3, 4 and 9 are less common, and very few cases exist for all subsequent types. The same review reports that mutations in TSEN54, RARS2, EXOSC3 and AMPD2 are the most common pathological mutations. Type 1C is a specific subtype within type 1, which is characterised by hypoplasia of the pons and cerebellum together with degeneration of motor neurons in the anterior horn of the spinal cord.
A 2007 case report describes a 4-year-old female with severe psychomotor retardation, microcephaly, generalised hypotonia, muscle hypotrophy, limb contractions, absent stretch reflex and neonatal-onset epilepsy. Brain MRI showed pontocerebellar hypoplasia, electroneuromyography indicated axonal neuropathy, and a deltoid muscle biopsy revealed neurogenic muscular atrophy. A mitochondrial respiratory chain study in muscle homogenate and skin fibroblasts found complex IV values at the lower limits of normal. Genetic testing for spinal muscular atrophy was negative. A 2023 case report describes a male infant, born at 36 weeks and 6 days, with a diagnosis of type 1D pontocerebellar hypoplasia resulting from alteration of the EXOSC9 gene. His birth measurements were height 44.5 cm, weight 2.660 kg, and head circumference 33.8 cm.
The diagnosis of pontocerebellar hypoplasia generally indicates severe developmental delay, epilepsy and neurodegeneration in childhood. Neuroradiographic features are complex and evolve over time, affecting the pons, cerebellum, vermis, cortex and cerebral white matter. The 2007 case report notes that mitochondrial respiratory chain studies may be of interest in understanding the disorder, but no treatment or disease-modifying intervention is described in any of these abstracts. What remains missing are prospective natural history studies, validated biomarkers for disease progression, and any clinical trial data that could support a specific therapeutic approach. Patient stratification by genotype is not yet standardised outside research settings, and funding for such rare disease work is limited.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics Part C Seminars in Medical Genetics · 2014 · 93 citations
Pontocerebellar hypoplasia
AbstractPontocerebellar hypoplasia (PCH) is a clinically and genetically heterogeneous group of autosomal recessively inherited neurodevelopmental disorders. Following the rapidly increasing number of genes identified in different subtypes, the clinical spectrum has been broadened to completely different neurological phenotypes. In this review we will address the clinical picture, neuroradiological, pathoanatomic, and genetic findings in the currently known PCH subtypes.
Brain Communications · 2025 · 4 citations · open access
Pontocerebellar hypoplasia: a review from 1912 to 2022
AbstractAbstract Pontocerebellar hypoplasia is a rare neurodevelopmental disorder that results from differences in formation and function of the pons, cerebellum and cerebrum. It can be diagnosed prenatally or postnatally with a combination of clinical, neuroimaging and genetic data obtained over time. The diagnosis of pontocerebellar hypoplasia usually portends severe developmental delay, epilepsy and/or neurodegeneration in childhood. Here we perform a comprehensive review with the primary goal of evaluating published evidence addressing the clinical and genetic features of pontocerebellar hypoplasia by type and subtype. Secondly, we summarize neurodiagnostic patterns of pontocerebellar hypoplasia and demonstrate its spectrum. Finally, we provide recommendations in diagnosis, prognosis and management for the neurologist. To address these goals, we performed an extensive review of published literature from 1912 to 2022. We identified 191 publications by combining search results from PubMed, OMIM and cross-referenced bibliographies. Publications on developmental neuroanatomy, not pertaining to pontocerebellar hypoplasia or published in a foreign language were excluded. We performed both qualitative (1912–1993) and quantitative (1993–2022) analyses to understand the current classification of this disease as it pertains to genetic and neurodiagnostic features of pontocerebellar hypoplasia by type and subtype. Our review shows that the most reported types of pontocerebellar hypoplasia are 1, 2 and 6; less frequently described are 3, 4 and 9. Very few cases are described for all other subsequent pontocerebellar hypoplasia types. Mutations in TSEN54, RARS2, EXOSC3 and AMPD2 (genes that regulate RNA processing and basic cellular metabolism) are the most frequently reported pathological mutations in pontocerebellar hypoplasia. The neuroradiographic features of pontocerebellar hypoplasia are complex and evolve over time, affecting the pons, cerebellum, vermis, cortex and cerebral white matter. In conclusion, pontocerebellar hypoplasia is a rare neurodevelopmental disorder, often the result of genetic dysfunction in basic neural metabolism. The diagnosis conveys significant implications for the affected individual and their families and requires a combination of clinical, neuroradiographic, and genetic testing to best inform type/subtype categorization of pontocerebellar hypoplasia.
Hipoplasia pontocerebelosa tipo 1: aportación de un caso
AbstractINTRODUCTION: Pontocerebellar hypoplasias constitute a group of hereditary neurodegenerative disorders of uncertain aetiopathogenesis. They have been reported as being associated with deficiencies of complexes in the mitochondrial respiratory chain (MRC) and with congenital disorders of glycosylation. On the basis of clinical and neuropathological criteria, two phenotypes can be distinguished in this condition. Pontocerebellar hypoplasia type 1 is characterised by hypoplasia of the pons and the cerebellum associated with the degeneration of the motor neurons in the anterior horn of the spinal cord. CASE REPORT: A 4-year-old female with symptoms of severe psychomotor retardation associated with microcephaly, important generalised hypotonia, muscle hypotrophy, contractions in the four limbs, absence of stretch reflex and epilepsy with onset in the neonatal period. Magnetic resonance imaging of the brain revealed pontocerebellar hypoplasia. An electroneuromyography showed a trace that was compatible with axonal neuropathy and a biopsy of the deltoid muscle revealed the existence of neurogenic muscular atrophy. In the MRC study conducted in muscle homogenate and in skin fibroblasts, complex IV values were found to be at the lower limits of what could be considered to be normal levels. Results of the genetic study for spinal muscular atrophy were negative. CONCLUSIONS: The case reported here could be included as a case of pontocerebellar hypoplasia type 1. MRC studies can be of interest in cases of pontocerebellar hypoplasia in order to explain the role it plays in this disorder.
Arquivos de Neuro-Psiquiatria · 2023 · 0 citations · open access
Case report: pontocerebellar hypoplasia type 1D
AbstractCase presentation: This report aims to describe the case of a patient with a rare diagnosis of type 1D pontocerebellar hypoplasia (PCH1D), resulting from the alteration of the EXOSC9 gene. G. T. S. D. S., male, 1 year and 2 months old, fruit of unplanned pregnancy of non-consanguineous parents. Prenatal care was complete. The patient was born by vaginal delivery without complications, with 36 weeks and 6 days of gestational age, and with the following measurements: height = 44.5 cm; weight = 2,660 kg; head circumference = 33.8 cm.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
